Atrophic gastritis and gastric cancer tissue miRNome analysis reveals hsa-miR-129-1 and hsa-miR-196a as potential early diagnostic biomarkers.
Atrophic gastritis
Biomarkers
Gastric cancer
Helicobacter pylori
MicroRNAs
Tumorigenesis
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Feb 2022
14 Feb 2022
Historique:
received:
13
09
2021
revised:
19
11
2021
accepted:
19
01
2022
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
25
3
2022
Statut:
ppublish
Résumé
Gastric cancer (GC) is one of the most frequently diagnosed tumor globally. In most cases, GC develops in a stepwise manner from chronic gastritis or atrophic gastritis (AG) to cancer. One of the major issues in clinical settings of GC is diagnosis at advanced disease stages resulting in poor prognosis. MicroRNAs (miRNAs) are small noncoding molecules that play an essential role in a variety of fundamental biological processes. However, clinical potential of miRNA profiling in the gastric cancerogenesis, especially in premalignant GC cases, remains unclear. To evaluate the AG and GC tissue miRNomes and identify specific miRNAs' potential for clinical applications ( Study included a total of 125 subjects: Controls (CON), AG, and GC patients. All study subjects were recruited at the Departments of Surgery or Gastroenterology, Hospital of Lithuanian University of Health Sciences and divided into the profiling ( Results of tissue analysis revealed 20 differentially expressed miRNAs in AG group compared to CON group, 129 deregulated miRNAs in GC compared to CON, and 99 altered miRNAs comparing GC and AG groups. Only 2 miRNAs (hsa-miR-129-1-3p and hsa-miR-196a-5p) were identified to be step-wise deregulated in healthy-premalignant-malignant sequence. Area under the curve (AUC)-receiver operating characteristic analysis revealed that expression level of hsa-miR-196a-5p is significant for discrimination of CON Comprehensive miRNome study provides evidence for gradual deregulation of hsa-miR-196a-5p and hsa-miR-129-1-3p in gastric carcinogenesis and found hsa-miR-215-3p/5p and hsa-miR-934 to be significantly deregulated in
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cancer (GC) is one of the most frequently diagnosed tumor globally. In most cases, GC develops in a stepwise manner from chronic gastritis or atrophic gastritis (AG) to cancer. One of the major issues in clinical settings of GC is diagnosis at advanced disease stages resulting in poor prognosis. MicroRNAs (miRNAs) are small noncoding molecules that play an essential role in a variety of fundamental biological processes. However, clinical potential of miRNA profiling in the gastric cancerogenesis, especially in premalignant GC cases, remains unclear.
AIM
OBJECTIVE
To evaluate the AG and GC tissue miRNomes and identify specific miRNAs' potential for clinical applications (
METHODS
METHODS
Study included a total of 125 subjects: Controls (CON), AG, and GC patients. All study subjects were recruited at the Departments of Surgery or Gastroenterology, Hospital of Lithuanian University of Health Sciences and divided into the profiling (
RESULTS
RESULTS
Results of tissue analysis revealed 20 differentially expressed miRNAs in AG group compared to CON group, 129 deregulated miRNAs in GC compared to CON, and 99 altered miRNAs comparing GC and AG groups. Only 2 miRNAs (hsa-miR-129-1-3p and hsa-miR-196a-5p) were identified to be step-wise deregulated in healthy-premalignant-malignant sequence. Area under the curve (AUC)-receiver operating characteristic analysis revealed that expression level of hsa-miR-196a-5p is significant for discrimination of CON
CONCLUSION
CONCLUSIONS
Comprehensive miRNome study provides evidence for gradual deregulation of hsa-miR-196a-5p and hsa-miR-129-1-3p in gastric carcinogenesis and found hsa-miR-215-3p/5p and hsa-miR-934 to be significantly deregulated in
Identifiants
pubmed: 35317427
doi: 10.3748/wjg.v28.i6.653
pmc: PMC8900545
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Mirn129 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
653-663Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors have declared no conflicts of interest.
Références
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Osteoarthritis Cartilage. 2016 May;24(5):763-4
pubmed: 26802548
Front Genet. 2019 Jun 19;10:592
pubmed: 31275362
PLoS One. 2015 Jul 14;10(7):e0132327
pubmed: 26172537
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Nat Rev Gastroenterol Hepatol. 2014 Nov;11(11):664-74
pubmed: 25134511
Oncogene. 2011 Mar 31;30(13):1577-85
pubmed: 21119604
Oncotarget. 2017 Jun 6;8(23):37225-37238
pubmed: 28402935
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Int J Cancer. 2011 Oct 1;129(7):1661-70
pubmed: 21128279
Genome Biol. 2014;15(12):550
pubmed: 25516281
United European Gastroenterol J. 2018 Jun;6(5):691-701
pubmed: 30083331
Lab Invest. 2016 Jun;96(6):661-71
pubmed: 26950485
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
BMC Cancer. 2019 Feb 8;19(1):129
pubmed: 30736753
Bioinform Biol Insights. 2015 Jul 06;9:111-7
pubmed: 26244015
Gastroenterology. 2015 Oct;149(5):1153-1162.e3
pubmed: 26073375
Adv Exp Med Biol. 2013;774:1-20
pubmed: 23377965
Onco Targets Ther. 2017 Nov 22;10:5551-5559
pubmed: 29200870
Med Oncol. 2014 Aug;31(8):98
pubmed: 25008064
Gut Liver. 2015 Mar;9(2):188-96
pubmed: 25167801
Br J Surg. 2010 Jun;97(6):853-61
pubmed: 20301167
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Cancer Sci. 2018 Feb;109(2):297-307
pubmed: 29215765
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
PLoS One. 2013 May 07;8(5):e62440
pubmed: 23667477
Eur J Cancer. 2016 Sep;64:137-48
pubmed: 27420607
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Nat Biotechnol. 2017 Apr 11;35(4):316-319
pubmed: 28398311
Oncotarget. 2016 Jan 26;7(4):4817-28
pubmed: 26716895
BMC Genomics. 2016 Oct 17;17(Suppl 9):751
pubmed: 27766962
Mol Med Rep. 2019 Aug;20(2):1966-1976
pubmed: 31257509
Dig Liver Dis. 2008 Aug;40(8):650-8
pubmed: 18424244
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Genet. 2016 Dec;17(12):719-732
pubmed: 27795564
World J Gastroenterol. 2011 Dec 28;17(48):5231-9
pubmed: 22219591
World J Gastroenterol. 2018 Aug 14;24(30):3313-3329
pubmed: 30122873
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Genes (Basel). 2021 Apr 19;12(4):
pubmed: 33921696
Int J Mol Sci. 2020 Jan 29;21(3):
pubmed: 32013265
Cancer Lett. 2014 Jan 1;342(1):27-35
pubmed: 23981575
Sci Rep. 2015 Feb 05;5:8270
pubmed: 25652892
Mol Cancer Ther. 2012 Apr;11(4):842-52
pubmed: 22343731
Front Cell Dev Biol. 2021 Jun 10;9:689947
pubmed: 34179017
Med Oncol. 2013 Mar;30(1):365
pubmed: 23307240